Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoid Interstitial Pneumonia 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1DNA Repair-Deficiency Disorders 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Clinical Stage I Gastric Cancer AJCC v8 1Cholangiocarcinoma 1

Interventions

Gemcitabine 19130-nm albumin-bound paclitaxel 16Specimen Handling 15Irinotecan 11Magnetic Resonance Spectroscopy 10Fluorouracil 10Leucovorin 9Biopsy 9Oxaliplatin 8pembrolizumab 7Cyclophosphamide 7fludarabine 6Cisplatin 5Pemetrexed 4Cetuximab 4Albumin-Bound Paclitaxel 4zimberelimab 3trastuzumab deruxtecan 3olaparib 3irinotecan sucrosofate 3durvalumab 3dehydroftorafur 3aldesleukin 3Taxes 3Radiosurgery 3Nivolumab 3Immunoglobulin G 3Disulfides 3Carboplatin 3veliparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × dehydroftorafur × 30 days × Clear all
NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Not yet recruiting
46 enrolled
Gastrointestinal

Pancreatic Neoplasms, Cholangiocarcinoma

NCT06998940 2026-05-22

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

SWOG Cancer Research Network

Phase 3 Recruiting
94 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02890355 2026-05-20

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
123 enrolled 15 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡